JCEM: Cardiometabolic Outcomes and Mortality in Patients with Adrenal Adenoma

Although adrenal adenoma and heart blood vessel -related morbidity, but the lack of large-scale population-based data
.

Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
The study aims to clarify the prevalence and incidence of cardiometabolic diseases and evaluate a population-based cohort of adrenal adenoma patients.
Death rate
.

The study was a population-based cohort study.
The subjects of the study were patients diagnosed with adrenal adenoma without significant hormone overdose and age- and gender-matched controls without adrenal adenoma
.
The main outcome indicators of the study were the prevalence, incidence and mortality of the cardiometabolic outcome

Cumulative incidence of cardiometabolic outcome and death during follow-up

1004 patients (58% were women, with a median age of 63 years) were diagnosed with adrenal adenoma
.
At baseline, compared with controls, patients with adrenal adenoma were more likely to have hypertension (aOR 1.

Thus, in a population-based cohort, adrenal adenomas are associated with increased prevalence and incidence of adverse cardiometabolic outcomes
.

Original source:

Catherine D Zhang.